Szafrański Wojciech, Polsce Jan Zieliński I Kierownicy Ośrodków Domowego Leczenia Tlenem W
Oddział Pulmonologiczny, Wojewódzki Szpital Specjalistyczny, ul. Aleksandrowicza 5, 26-617 Radom, Poland.
Pneumonol Alergol Pol. 2007;75(4):331-42.
Long-term domiciliary oxygen therapy (LTOT) is part to of pulmonary care system. Uniform qualification criteria and methods of follow-up for patients undergoing LTOT have been adopted. There are 63 LTOT centres located in Poland run by specialists in pulmonology. On the occasion of 20 years of LTOT in Poland, an analysis of its development, number of patients treated, diagnoses, survival and equipment was performed.
Data were taken from structurized LTOT centres reports.
A history of LTOT may be divided into 3 periods, steady grow in the years 1986-1991, stagnation between 1992-2000 and rapid grow in the last 3 years. On 01.01.2006 there was 2601 patients receiving LTOT therapy. The most common diagnosis was COPD (85%) followed by kyphoscolisis (5%), TB sequels (4.6%), IPF (3.6%) and other rare diseases. Treatment is reimbursed by the National Health System. Oxygen is administered via an oxygen concentrator. Due to insufficient resources from the NHS the needs for LTOT treatment are not fulfilled. There are 8.4 patients treated with LTOT per 100 000 people, with large regional differences ranging from 3.7 to 14.9/100 000. The most frequent cause of death in patients receiving LTOT treatment was exacerbation of respiratory failure (71.3%), followed by sudden death (5.1%), myocardial infarction or pulmonary embolism (4.4%), lung cancer (4%) and other or not known causes (15.2%). Survival in patients receiving LTOT treatment from the years 1986-1995 was rather short: 54.6% survived less than 3 years, 3-4 years survived 13.3%, 4-5 years 11.3% and more than 5 years survived 19.7% of treated patients.
长期家庭氧疗（LTOT）是肺部护理系统的一部分。对于接受LTOT治疗的患者，已经采用了统一的资格标准和随访方法。波兰有63个LTOT中心，由肺病专家管理。在波兰开展LTOT 20周年之际，对其发展、治疗患者数量、诊断、生存率和设备进行了分析。
数据取自结构化的LTOT中心报告。
LTOT的历史可分为3个时期，1986 - 1991年稳步增长，1992 - 2000年停滞，最近3年快速增长。2006年1月1日，有2601名患者接受LTOT治疗。最常见的诊断是慢性阻塞性肺疾病（COPD，85%），其次是脊柱后凸（5%）、肺结核后遗症（4.6%）、特发性肺纤维化（IPF，3.6%）和其他罕见疾病。治疗费用由国家卫生系统报销。通过制氧机提供氧气。由于国家卫生系统资源不足，LTOT治疗的需求未得到满足。每10万人中有8.4人接受LTOT治疗，地区差异很大，范围从每10万人3.7人到14.9人。接受LTOT治疗的患者最常见的死亡原因是呼吸衰竭加重（71.3%），其次是猝死（5.1%）、心肌梗死或肺栓塞（4.4%）、肺癌（4%）以及其他或不明原因（15.2%）。1986 - 1995年接受LTOT治疗的患者生存率相当低：54.6%的患者存活时间不到3年，存活3 - 4年的患者占13.3%，存活4 - 5年的患者占11.3%，存活超过5年的患者占接受治疗患者的19.7%。
